Core Insights - Bausch + Lomb reported a record fourth quarter and full-year performance for 2025, driven by broad-based revenue growth and accelerating profitability [4][6] - The company achieved an adjusted EBITDA of $330 million in Q4, up 27%, with a margin of 23.5%, marking the highest level since its IPO [1][6] - Total revenue for Q4 was $1.405 billion, reflecting a 7% increase on a constant-currency basis, while full-year revenue reached $5.101 billion, up 5% [2][6] Financial Performance - Full-year adjusted EBITDA was $891 million, with an adjusted EBITDA margin of 17.5% [1] - The company expects 2026 revenue guidance of $5.375 to $5.475 billion, representing 5% to 7% constant-currency growth [5][15] - Adjusted EBITDA for 2026 is projected to be between $1.0 billion and $1.05 billion, implying an EBITDA margin of approximately 19% [5][16] Segment Performance - Vision Care segment revenue in Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [7] - The surgical segment reported Q4 revenue of $249 million, up 3%, and full-year revenue of $894 million, up 4% [8] - In pharmaceuticals, Q4 revenue was $378 million, up 14%, with full-year revenue of $1.284 billion, up 6% [9] Product Highlights - The dry-eye franchise saw significant growth, with MIEBO prescriptions increasing by 113% year-over-year, and peak sales potential raised from approximately $500 million to over $600 million [6][12] - XIIDRA also showed record quarterly prescriptions, with expected improved net pricing to drive revenue growth [13] - The consumer dry eye portfolio generated $116 million in Q4 revenue, up 6%, led by Blink growth of 33% [11] Market Dynamics - The overall dry eye market is expanding due to factors such as aging, environmental conditions, and increased screen time, with only about one in ten patients currently treated with prescription therapy [14] - Management noted that Q1 is typically the lowest quarter and Q4 the highest, with this seasonality expected to become more pronounced as the dry eye franchise grows [18] Future Outlook - The company plans to launch new consumer products, including PreserVision AREDS 3 and Blink Triple Care, in early 2026 [19] - A CE Mark submission for a next-generation femtosecond laser, Silera, is anticipated soon, with expected approval in the second half of the year [19] - Management is optimistic about returning to pre-recall levels in the surgical segment and expects to stop referencing the enVista recall in future earnings calls [21]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue reached $5.101 billion, up 5% [13][22] - Adjusted EBITDA for Q4 was $330 million, reflecting a 27% growth year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [12][20] - The full-year adjusted EBITDA was $891 million, with a margin of 17.5% [9][20] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [15] - Surgical segment revenue in Q4 was $249 million, a 3% increase, and full-year revenue was $894 million, up 4% [17] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [18] Market Data and Key Metrics Changes - The U.S. branded RX business in the pharma segment grew by 21% in Q4 and 13% for the full year [18] - Contact lens revenue growth was 8% in Q4 and 7% for the full year, with daily SiHy lenses up 17% in Q4 and 28% for the full year [16] - In China, contact lenses grew by 7% in Q4 and 8% for the full year [16] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline [5][6] - The strategy includes expanding the dry eye portfolio, with MIEBO expected to exceed $600 million in peak sales due to strong market access and execution [26][41] - The company aims to leverage its diversified product portfolio to drive sustained growth in the eye health market [11][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow faster than the market in 2026, with revenue guidance of $5.375 billion to $5.475 billion [22][23] - The company anticipates continued margin expansion and operating leverage, with adjusted EBITDA growth expected to outpace revenue growth [23][24] - Management highlighted the importance of execution and structural improvements in the P&L as key drivers of future performance [36][38] Other Important Information - The company reported an adjusted gross margin of 62.1% for Q4 and 61% for the full year [19] - Adjusted cash flow from operations was $152 million in Q4 and $381 million for the full year [20] - The adjusted tax rate for the full year was 10%, lower than previous guidance due to one-time adjustments [21] Q&A Session Summary Question: What are the key areas to execute for growth in 2026? - Management emphasized the importance of execution, structural improvements, and aligning the organization around clear priorities to achieve growth [36][38] Question: What lessons can be learned from MIEBO's success? - The success of MIEBO is attributed to a strong product with a favorable benefit-risk profile and effective execution strategies [40][43] Question: How does the company view the competitive landscape for 2026? - Management acknowledged competition but expressed confidence in their market position, particularly in the pharma segment with strong access and momentum [53][56]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue of $5.101 billion, up 5% [13][22] - Adjusted EBITDA for Q4 was $330 million, a 27% increase year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [12][20] - The full-year adjusted EBITDA was $891 million, reflecting a strong operating leverage and financial discipline [20][23] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [15] - Surgical segment revenue in Q4 was $249 million, a 3% increase, with full-year revenue of $894 million, up 4% [17] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [18] Market Data and Key Metrics Changes - The U.S. branded RX business in the pharma segment grew by 21% in Q4 and 13% for the full year, driven by strong performance from MIEBO [18] - Contact lens revenue grew by 8% in Q4 and 7% for the full year, with daily SiHy lenses showing significant growth [16] - The international market for contact lenses grew by 6% in Q4, with China seeing a 7% increase [16] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline to drive sustained growth [5][6] - There is a strong commitment to expanding the dry eye portfolio, with MIEBO expected to exceed peak sales of $600 million due to its successful market penetration [26][27] - The company aims to leverage its diversified product offerings to maintain a competitive advantage in the eye health market [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow faster than the market in 2026, with expectations for revenue growth across all segments [22][23] - The company highlighted the importance of execution and operational improvements as key drivers of future success [36][38] - Management acknowledged the competitive landscape but remains optimistic about the company's positioning and product quality [53][56] Other Important Information - The company expects adjusted EBITDA growth of approximately 15% year-over-year for 2026, with a focus on margin expansion [23][24] - The adjusted tax rate for the full year 2025 was 10%, lower than previous guidance, primarily due to one-time adjustments [21] Q&A Session Summary Question: What are the key areas to execute for growth in 2026? - Management emphasized the importance of execution and structural improvements in the P&L, highlighting the successful implementation of Vision 2027 [36][38] Question: What lessons can be learned from MIEBO's success? - Management noted that strong execution and a positive benefit-risk profile contributed to MIEBO's success, which will inform future pipeline strategies [40][41] Question: How will MIEBO's growth trajectory be impacted by steady investments? - Management expects continued strong growth for MIEBO, with a focus on targeted investments as the product transitions from launch to growth phase [48][51] Question: What are the competitive dynamics in the market? - Management acknowledged competition but expressed confidence in their strong market position, particularly in the pharma segment with leading products [53][56]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue reached $5.101 billion, up 5% [12][18] - Adjusted EBITDA for Q4 was $330 million, reflecting a 27% growth year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [11][18] - The adjusted gross margin for Q4 was 62.1%, with a full-year adjusted gross margin of 61% [17] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [13] - Surgical segment revenue in Q4 was $249 million, a 3% increase, with full-year revenue of $894 million, up 4% [15] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [16] Market Data and Key Metrics Changes - The U.S. contact lens market grew by 11% in Q4, while international markets saw a 6% increase [14] - In China, contact lens revenue grew by 7% in Q4 and 8% for the full year [14] - The global dry eye market is expected to nearly double in the next four years, with significant growth attributed to MIEBO [27] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline [4][20] - The strategy includes expanding the dry eye portfolio and leveraging R&D to drive revenue growth [6][10] - The company aims to achieve revenue growth faster than the market across all segments in 2026 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong execution and a solid foundation for future success [39] - The company anticipates continued momentum in 2026, with expectations for revenue growth in the range of $5.375 billion to $5.475 billion [20] - Management highlighted the importance of disciplined execution and the impact of seasonality on revenue, particularly in the dry eye segment [68] Other Important Information - The company plans to maintain investments in R&D at 7.5%-8% of revenue, with adjusted EBITDA guidance for 2026 set between $1 billion and $1.05 billion [21][22] - The adjusted tax rate for 2026 is expected to be approximately 19% [22] Q&A Session Summary Question: What are the key areas to execute on for growth in 2026? - Management emphasized the importance of execution, structural improvements in the P&L, and aligning the organization around clear priorities [35][36] Question: What lessons can be learned from MIEBO's success? - Management noted that strong execution and a positive benefit-risk profile contributed to MIEBO's success, and these lessons will inform future pipeline strategies [40][41] Question: How will XIIDRA perform in 2026? - Management expects mid-single-digit sales growth for XIIDRA, balancing net price improvement with volume decline [77][80]

Core Insights - Bausch + Lomb reported a GAAP revenue growth of 5% year over year to $1.278 billion, exceeding analyst expectations by $18 million [1] - Adjusted EPS (non-GAAP) was $0.07, beating consensus estimates by $0.01 but down 46.2% from $0.13 in the previous year [2] - The company experienced a narrowed net loss of $62 million compared to $151 million a year earlier, indicating some operational improvement [2][8] Business Overview - Bausch + Lomb specializes in eye health products, including contact lenses, OTC consumer eye care brands, prescription pharmaceuticals, and surgical devices, operating in three segments: Vision Care, Surgical, and Pharmaceuticals [3] Strategic Focus - The growth strategy includes a broad product portfolio, separation from Bausch Health Companies, geographic expansion, and investment in R&D, while managing regulatory risks and increasing scale in consumer and surgical markets [4] Quarterly Performance - Vision Care segment revenue reached $753 million, up 8% year over year, driven by daily silicone hydrogel contact lenses and consumer brands [5] - Surgical segment revenue was $216 million, growing 3% year over year, despite a voluntary recall of certain enVista IOL products [6] - Pharmaceuticals revenue declined to $309 million, attributed to weak US generics performance and pricing pressures [7] Profitability Metrics - Adjusted EBITDA (non-GAAP) decreased to $191 million, reflecting higher spending on marketing and costs from the recall [8] - Cash flow from operations improved to $35 million, a 133.3% increase from the previous year, due to better working capital management [2][8] Research and Development - R&D expenses increased to $96 million, with around 60 projects underway, including next-generation contact lenses and therapeutics for glaucoma and dry eye disease [9] Future Guidance - Full-year 2025 revenue guidance was raised to $5.05 billion to $5.15 billion, with projected constant currency revenue growth between 5% and 7% [10] - Adjusted EBITDA guidance for 2025 is set at $860 million to $910 million, driven by demand in Vision Care and Surgical [10] Key Watch Points - Management highlighted potential tariff impacts on adjusted EBITDA margin, estimating a 120 basis point headwind in the second half of 2025 [11] - Ongoing cost control, stabilization of Pharmaceuticals, and new product rollouts in Vision Care and Surgical are critical areas to monitor [11]